Review of Cohort Studies for Mood Disorders

키워드

참고문헌 (127)

1. Kessler RC, "The global burden of mental disorders : an update from the WHO World Mental Health(WMH)surveys", Epidemiol Psichiatr Soc, 18, pp.23~33 (2009)
2. Simon GE, "Social and economic burden of mood disorders", Biol Psychiatry, 54, pp.208~215 (2003)
3. Jeon HJ, "Lifetime prevalence and correlates of suicidal ideation, plan, and single and multiple attempts in a Korean nationwide study", J Nerv Ment Dis, 198, pp.643~646 (2010)
4. Jeon HJ, "Unplanned versus planned suicide attempters, precipitants, methods, and an association with mental disorders in a Korea-based community sample", J Affect Disord, 127, pp.274~280 (2010)
5. Jeon HJ, "Differences in depressive symptoms between Korean and American outpatients with major depressive disorder", Int Clin Psychopharmacol, 29, pp.150~156 (2014)
6. Jeon HJ, "Feelings of worthlessness, traumatic experience, and their comorbidity in relation to lifetime suicide attempt in community adults with major depressive disorder", J Affect Disord, 166, pp.206~212 (2014)
7. Munoz A, "Methodological issues for biomarkers and intermediate outcomes in cohort studies", Epidemiol Rev, 20, pp.29~42 (1998)
8. Hagnell O, "A prospective study concerning mental disorders of a total population investigated in 1947, 1957 and 1972. The Lundby study III (preliminary report)", Acta Psychiatr Scand Suppl, 263, pp.1~11 (1975)
9. Patient Register, "The National Board of Health and Welfare", National Board of Health and Welfare, ~ (2004)
10. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders", American Psychiatric Association, ~ (2000)
11. Mattisson C, "The long-term course of depressive disorders in the Lundby Study", Psychol Med, 37, pp.883~891 (2007)
12. Nettelbladt P, "Does it make sense to do repeated surveys?--the Lundby Study, 1947-1997", Acta Psychiatr Scand, 111, pp.444~452 (2005)
13. Angst J, "The Zurich study--a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. I. Problem, methodology", Eur Arch Psychiatry Neurol Sci, 234, pp.13~20 (1984)
14. Derogatis LR, "Factorial invariance across gender for the primary symptom dimensions of the SCL-90", Br J Soc Clin Psychol, 16, pp.347~356 (1977)
15. Burns T, "Which individuals with affective symptoms seek help? Results from the Zurich epidemiological study", Acta Psychiatr Scand, 108, pp.419~426 (2003)
16. Eich D, "Is depression a risk factor for heart complaints? Longitudinal aspects in the Zurich study", Eur Arch Psychiatry Clin Neurosci, 257, pp.396~401 (2007)
17. Merikangas KR, "Longitudinal trajectories of depression and anxiety in a prospective community study : the Zurich Cohort Study", Arch Gen Psychiatry, 60, pp.993~1000 (2003)
18. Angst J, "Does psychomotor agitation in major depressive episodes indicate bipolarity? Evidence from the Zurich Study", Eur Arch Psychiatry Clin Neurosci, 259, pp.55~63 (2009)
19. Merikangas KR, "Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders : results from the Zurich cohort study", Arch Gen Psychiatry, 65, pp.47~52 (2008)
20. Katz MM, "Introduction : overview of the clinical studies program", Am J Psychiatry, 136, pp.49~51 (1979)
21. Endicott J, "A diagnostic interview : the schedule for affective disorders and schizophrenia", Arch Gen Psychiatry, 35, pp.837~844 (1978)
22. Manni E, "Afferent fibers and sensory ganglion cells within the oculomotor nerve in some mammals and man. II. Electrophysiological investigations", Arch Ital Biol, 116, pp.16~24 (1978)
23. Keller MB, "The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies", Arch Gen Psychiatry, 44, pp.540~548 (1987)
24. Leon AC, "The Range of Impaired Functioning Tool(LIFE-RIFT) : a brief mea sure of functional impairment", Psychol Med, 29, pp.869~878 (1999)
25. Judd LL, "Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders", J Affect Disord, 108, pp.49~58 (2008)
26. Judd LL, "Major depressive disorder : a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse", J Affect Disord, 50, pp.97~108 (1998)
27. Judd LL, "Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study", Arch Gen Psychiatry, 62, pp.1322~1330 (2005)
28. Judd LL, "Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse", recurrence, 2008, pp.65, 386~394
29. Coryell W, "Anxiety and outcome in bipolar disorder", Am J Psychiatry, 166, pp.1238~1243 (2009)
30. Judd LL, "The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders?", J Affect Disord, 73, pp.19~32 (2003)
31. Judd LL, "The long-term natural history of the weekly symptomatic status of bipolar I disorder", Arch Gen Psychiatry, 59, pp.530~537 (2002)
32. Judd LL, "A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder", Arch Gen Psychiatry, 60, pp.261~269 (2003)
33. Judd LL, "Major depressive disorder: longitudinal symptomatic structure, relapse and recovery", Acta Psychiatr Scand, 104, pp.81~83 (2001)
34. Fava M, "Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study", Psychiatr Clin North Am, 26, pp.457~494 (2003)
35. Sachs GS, "Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)", Biol Psychiatry, 53, pp.1028~1042 (2003)
36. Penninx BW, "The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods", Int J Methods Psychiatr Res, 17, pp.121~140 (2008)
37. Kessler RC, "Clinical calibration of DSM-IV diagnoses in the World Mental Health(WMH)version of the World Health Organization(WHO)Composite International Diagnostic Interview(WMHCIDI)", Int J Methods Psychiatr Res, 13, pp.122~139 (2004)
38. Rush AJ, "Sequenced treatment alternatives to relieve depression(STAR*D) : rationale and design", Control Clin Trials, 25, pp.119~142 (2004)
39. Zimmerman M, "The reliability and validity of a screening Questionnaire for 13 DSM-IV Axis I disorders(the Psychiatric Diagnostic Screening Questionnaire)in psychiatric outpatients", J Clin Psychiatry, 60, pp.677~683 (1999)
40. Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
41. Rush AJ, "The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression", Biol Psychiatry, 54, pp.573~583 (2003)
42. Busner J, "The Clinical Global Impressions scale : errors in understanding and use", Compr Psychiatry, 50, pp.257~262 (2009)
43. Alpert JE, "Enrolling research subjects from clinical practice : ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression(STAR*D)trial", Psychiatry Res, 141, pp.193~200 (2006)
44. Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
45. Gaynes BN, "A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial", Gen Hosp Psychiatry, 27, pp.87~96 (2005)
46. Nierenberg AA, "A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report", Am J Psychiatry, 163, pp.1519~1530 (2006)
47. McGrath PJ, "Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report", Am J Psychiatry, 163, pp.1531~1541 (2006)
48. Thase ME, "Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments : a STAR*D report", Am J Psychiatry, 164, pp.739~752 (2007)
49. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders", American Psychiatric Association, ~ (2013)
50. Gilmer WS, "Factors associated with chronic depressive episodes : a preliminary report from the STAR-D project", Acta Psychiatr Scand, 112, pp.425~433 (2005)
51. Perlis RH, "Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder", Arch Gen Psychiatry, 68, pp.351~360 (2011)
52. Perlis RH, "Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder", Acta Psychiatr Scand, 119, pp.282~289 (2009)
53. Yates WR, "Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D", Gen Hosp Psychiatry, 26, pp.421~429 (2004)
54. Bryan CJ, "A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes : a STAR*D report", J Affect Disord, 108, pp.113~120 (2008)
55. Kozel FA, "Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode : a Sequenced Treatment Alternatives to Relieve Depression(STAR*D)report", Am J Geriatr Psychiatry, 16, pp.58~64 (2008)
56. Gilmer WS, "Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report", J Clin Psychiatry, 69, pp.1246~1256 (2008)
57. Binder EB, "Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response", Arch Gen Psychiatry, 67, pp.369~379 (2010)
58. Laje G, "Genetic markers of suicidal ideation emerging during citalopram treatment of major depression", Am J Psychiatry, 164, pp.1530~1538 (2007)
59. Warden D, "What predicts attrition in second step medication treatments for depression? : a STAR*D Report", Int J Neuropsychopharmacol, 12, pp.459~473 (2009)
60. Cabanero M, "Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample", Pharmacogenet Genomics, 19, pp.235~238 (2009)
61. Paddock S, "Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort", Am J Psychiatry, 164, pp.1181~1188 (2007)
62. Perlis RH, "Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study", Arch Gen Psychiatry, 64, pp.689~697 (2007)
63. Perlis RH, "Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response : association of TREK1 and treatment resistance in the STAR(*)D study", Neuropsychopharmacology, 33, pp.2810~2819 (2008)
64. Lekman M, "The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression(STAR*D)Cohort", Biol Psychiatry, 63, pp.1103~1110 (2008)
65. Bowden CL, "Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder(STEP-BD)", CNS Neurosci Ther, 18, pp.243~249 (2012)
66. Sheehan DV, "The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10", J Clin Psychiatry, 59(Suppl 20), pp.22~33 (1998)
67. Sachs GS, "Use of clonazepam for bipolar affective disorder", J Clin Psychiatry, 51(Suppl 31-34), pp.50~53 (1990)
68. Williams JB, "Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale(SIGMA)", Br J Psychiatry, 192, pp.52~58 (2008)
69. Young RC, "A rating scale for mania: reliability, validity and sensitivity", Br J Psychiatry, 133, pp.429~435 (1978)
70. Liebowitz MR, "Social phobia", Mod Probl Pharmacopsychiatry, 22, pp.141~173 (1987)
71. Shear MK, "Multicenter collaborative panic disorder severity scale", Am J Psychiatry, 154, pp.1571~1575 (1997)
72. Goodman WK, "The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability", Arch Gen Psychiatry, 46, pp.1006~1011 (1989)
73. Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
74. McCrae RR, "An introduction to the five-factor model and its applications", J Pers, 60, pp.175~215 (1992)
75. Beck AT, "An inventory for measuring clinical anxiety : psychometric properties", J Consult Clin Psychol, 56, pp.893~897 (1988)
76. Ware JE Jr., "The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection", Med Care, 30, pp.473~483 (1992)
77. Harel EV, "Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression : a review", Isr J Psychiatry Relat Sci, 45, pp.121~128 (2008)
78. Ghaemi SN, "Antidepressant discontinuation in bipolar depression : a Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD)randomized clinical trial of long-term effectiveness and safety", J Clin Psychiatry, 71, pp.372~380 (2010)
79. Goldberg JF, "Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms : findings from the STEP-BD", Am J Psychiatry, 164, pp.1348~1355 (2007)
80. Bauer MS, "Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD)", J Clin Psychiatry, 67, pp.48~55 (2006)
81. Nierenberg AA, "Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone", Am J Psychiatry, 163, pp.210~216 (2006)
82. Miklowitz DJ, "Intensive psychosocial intervention enhances functioning in patients with bipolar depression : results from a 9-month randomized controlled trial", Am J Psychiatry, 164, pp.1340~1347 (2007)
83. Perlis RH, "Predictors of recurrence in bipolar disorder : primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD)", Am J Psychiatry, 163, pp.217~224 (2006)
84. Magalhaes PV, "Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder", Acta Psychiatr Scand, 125, pp.303~308 (2012)
85. Goldberg JF, "Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD", Am J Psychiatry, 166, pp.173~181 (2009)
86. Simon NM, "The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder", J Psychiatr Res, 41, pp.255~264 (2007)
87. Otto MW, "Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders", Br J Psychiatry, 189, pp.20~25 (2006)
88. Ghaemi SN, "Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants", Psychiatr Serv, 57, pp.660~665 (2006)
89. Brooks JO 3rd, "Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder : findings from the Systematic Treatment Enhancement Program for Bipolar Disorder", J Clin Psychiatry, 72, pp.240~247 (2011)
90. Huang J, "Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression", Am J Psychiatry, 167, pp.1254~1263 (2010)
91. Mansour HA, "Serotonin gene polymorphisms and bipolar I disorder : focus on the serotonin transporter", Ann Med, 37, pp.590~602 (2005)
92. Drago A, "GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment", Eur Neuropsychopharmacol, 23, pp.887~894 (2013)
93. Drago A, "The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample", Am J Med Genet B Neuropsychiatr Genet, 156B, pp.975~986 (2011)
94. Howrigan DP, "Using linkage information to weight a genome-wide association of bipolar disorder", Am J Med Genet B Neuropsychiatr Genet, 156B, pp.462~471 (2011)
95. Post RM, "The Stanley Foundation Bipolar Network. I. Rationale and methods", Br J Psychiatry Suppl, 41, pp.s169~s176 (2001)
96. P) Biometrics Research, "Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I", pp.2002, First MB
97. Denicoff KD, "Validation of the prospective NIMH-Life-Chart Method(NIMH-LCM-p)for longitudinal assessment of bipolar illness", Psychol Med, 30, pp.1391~1397 (2000)
98. Born C, "Saving time and money : a validation of the self ratings on the prospective NIMH Life-Chart Method(NIMH-LCM)", BMC Psychiatry, 14, pp.130~ (2014)
99. Rush AJ, "The Inventory for Depressive Symptomatology(IDS) : preliminary findings", Psychiatry Res, 18, pp.65~87 (1986)
100. Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
101. "Psychiatr Pol", 1993, 129~138
102. Altshuler L, "The Life Functioning Questionnaire (LFQ): a brief, gender-neutral scale assessing functional outcome", Psychiatry Res, 112, pp.161~182 (2002)
103. Post RM, "An overview of recent findings of the Stanley Foundation Bipolar Network(Part I)", Bipolar Disord, 5, pp.310~319 (2003)
104. Altshuler LL, "Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants", Am J Psychiatry, 163, pp.313~315 (2006)
105. Post RM, "Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers", Bipolar Disord, 3, pp.259~265 (2001)
106. Keck PE Jr, "Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder", Biol Psychiatry, 60, pp.1020~1022 (2006)
107. Frye MA, "A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression", Am J Psychiatry, 164, pp.1242~1249 (2007)
108. Nolen WA, "Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study", Acta Psychiatr Scand, 115, pp.360~365 (2007)
109. McElroy SL, "Open-label adjunctive topiramate in the treatment of bipolar disorders", Biol Psychiatry, 47, pp.1025~1033 (2000)
110. Suppes T, "Lamotrigine for the treatment of bipolar disorder : a clinical case series", J Affect Disord, 53, pp.95~98 (1999)
111. Suppes T, "Tiagabine in treatment refractory bipolar disorder : a clinical case series", Bipolar Disord, 4, pp.283~289 (2002)
112. Hummel B, "Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design", Bipolar Disord, 4, pp.412~417 (2002)
113. McElroy SL, "Olanzapine in treatment-resistant bipolar disorder", J Affect Disord, 49, pp.119~122 (1998)
114. Suppes T, "Use of quetiapine in bipolar disorder : a case series with prospective evaluation", Int Clin Psychopharmacol, 19, pp.173~174 (2004)
115. Leverich GS, "Early physical and sexual abuse associated with an adverse course of bipolar illness", Biol Psychiatry, 51, pp.288~297 (2002)
116. McElroy SL, "Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder", Am J Psychiatry, 158, pp.420~426 (2001)
117. Frye MA, "Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder", Am J Psychiatry, 160, pp.883~889 (2003)
118. Altshuler LL, "Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network", Am J Psychiatry, 167, pp.708~715 (2010)
119. Shivakumar G, "Are bipolar mood symptoms affected by the phase of the menstrual cycle?", J Womens Health, 17, pp.473~478 (2008)
120. Park MH, "Clinical characteristics of depressed patients with a history of suicide attempts : results from the CRESCEND study in South Korea", J Nerv Ment Dis, 198, pp.748~754 (2010)
121. Hamilton M, "The assessment of anxiety states by rating", Br J Med Psychol, 32, pp.50~55 (1959)
122. Overall J, "The Brief Psychiatric Rating Scale", Psychol Rep, 10, pp.779~812 (1962)
123. Beck AT, "Assessment of suicidal intention : the Scale for Suicide Ideation", J Consult Clin Psychol, 47, pp.343~352 (1979)
124. The WHOQOL Group, "Development of the World Health Organization WHOQOL-BREF quality of life assessment", Psychol Med, 28, pp.551~558 (1998)
125. 김태석, "The Clinical Research Center for Depression Study: Baseline Characteristics of a Korean Long-Term Hospital-Based Observational Collaborative Prospective Cohort Study", PSYCHIATRY INVESTIGATION, 8(1), pp.1~8 (2011), 대한신경정신의학회
126. Kim JM, "Predictors of 12-week remission in a nationwide cohort of people with depressive disorders : the CRESCEND study", Hum Psychopharmacol, 26, pp.41~50 (2011)
127. Yang SJ, "Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort : the CRESCEND study", Psychiatry Res, 189, pp.82~90 (2011)

관련 논문AI추천